We're here to support you with useful resources about Tzield, Early Detection and to prepare you and your team for the first Tzield infusion.
Infusion Readiness Tools
Dosing Calculator
Want an easy way to calculate the TZIELD dosing regimen? This dosing calculator helps you to quickly and accurately determine doses for your patients. A practical resource to share with colleagues and your MDT unit during TZIELD infusions.
Educational material
Tzield Efficacy and Safety Information
Read about the TZIELD TN-10 trial efficacy and safety data in a concise, easy-access format.
Download efficacy & safety data
Early Detection Support
Support for early type 1 diabetes detection, recommended monitoring, and identifying eligible patients for TZIELD.
Download early detection supportPeer Perspectives
What are your peers saying?
Hear from Professor Parth Narendran, Dr Renuka Dias, Dr Theodora Papanikolau and Jenny Cooper, who are sharing their experience with Teplizumab.
INDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1
MDT, multi-disciplinary team; T1D, Type 1 diabetes.
Useful Links
By following the links below, you will be directed to independent websites which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the websites.
2025 BSPED Paediatric Guidelines
Guidelines commissioned and developed by the British Society for Paediatric Endocrinology and Diabetes (BSPED).
View the BSPED Guideline →
2024 ISPAD Clinical Practice Consensus Guidelines
Clinical international recommendations for children, adolescents and young adults with diabetes from ISPAD.
View the ISPAD Guideline →
ABCD Early T1D Website
A hub created by the Association of British Clinical Diabetes, where a range of health care resources on the topic of early T1D are available.
Visit the ABCD website →
ELSA Study
The ELSA Study is screening children in the United Kingdom (UK) aged 2–17 years to assess the risk of developing T1D.
View the ELSA study →
T1DRA Study
The T1DRA Study is screening UK general population adults aged 18–70 to assess the risk of developing T1D.
View the T1DRA study →Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1
ABCD, Association of British Clinical Diabetologists; BSPED, British Society for Paediatric Endocrinology and Diabetes; ISPAD, International Society for Pediatric and Adolescent Diabetes; MDT, multi-disciplinary team; T1D, Type 1 diabetes.
- TZIELD® (teplizumab) UK Summary of Product Characteristics. 2025.
MAT-XU-2600465 (v1.0) | March 2026